74 related articles for article (PubMed ID: 1654145)
1. Attempt to augment the anti-proliferative effect of recombinant human lymphotoxin in combined use with anti-tumor antibody-diethyldithiocarbamate conjugates.
Mashiba H; Matsunaga K
Eur Cytokine Netw; 1991; 2(3):195-9. PubMed ID: 1654145
[TBL] [Abstract][Full Text] [Related]
2. Augmented antiproliferative effect of tumor necrosis factor (TNF), lymphotoxin and glycyrrhizin in combined use with diethyldithiocarbamate on Meth A tumor cells in vitro.
Mashiba H; Matsunaga K
Jpn J Exp Med; 1990 Apr; 60(2):67-71. PubMed ID: 2166841
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of cytostatic effect of recombinant human lymphotoxin and involvement of glutathione redox cycle.
Matsunaga K; Mashiba H
Eur Cytokine Netw; 1992; 3(3):307-11. PubMed ID: 1498261
[TBL] [Abstract][Full Text] [Related]
4. [Augmentation of TNF- and lymphotoxin-mediated cytotoxic effect in the combined use of ACNU and involvement of oxygen free radicals].
Matsunaga K; Mashiba H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):452-8. PubMed ID: 2321976
[TBL] [Abstract][Full Text] [Related]
5. Device for intracellular increase of oxygen free radicals and inhibition of MethA tumour cell proliferation: in vitro and in vivo studies.
Mashiba H; Matsunaga K
Int J Tissue React; 1988; 10(5):273-80. PubMed ID: 2855073
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of radiosensitizing effect of the nitroimidazole derivative RK28 on the proliferation of MethA tumor cells in combined use with diethyldithiocarbamate.
Mashiba H; Matsunaga K; Hata K
Life Sci; 1991; 49(19):1419-25. PubMed ID: 1658511
[TBL] [Abstract][Full Text] [Related]
7. Differences in the bioactivity of recombinant human TNF, LT, and T-cell-derived LT-3 on transformed cells in vitro and the Meth A tumor growing in BALB/c mice.
Granger GA; Masunaka I; Averbook B; Kobayashi M; Fitzgerald M; Yamamoto R
J Biol Response Mod; 1988 Oct; 7(5):488-97. PubMed ID: 3263472
[TBL] [Abstract][Full Text] [Related]
8. Immunotargeting approach utilizing production of oxygen free radicals.
Mashiba H; Matsunaga K
Cancer Lett; 1990 Dec; 55(3):183-8. PubMed ID: 2175248
[TBL] [Abstract][Full Text] [Related]
9. Augmented anti-proliferative effect in combined use of human lymphotoxin with a nitrosourea derivative, ACNU, and the involvement of glutathione redox cycle.
Mashiba H; Matsunaga K; Kakutani T
Int J Immunopharmacol; 1991; 13(4):333-8. PubMed ID: 2050437
[TBL] [Abstract][Full Text] [Related]
10. In vivo radiosensitization by diethyldithiocarbamate.
Kent CR; Blekkenhorst GH
Radiat Res; 1988 Dec; 116(3):539-46. PubMed ID: 2849781
[TBL] [Abstract][Full Text] [Related]
11. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species.
Pober JS; Lapierre LA; Stolpen AH; Brock TA; Springer TA; Fiers W; Bevilacqua MP; Mendrick DL; Gimbrone MA
J Immunol; 1987 May; 138(10):3319-24. PubMed ID: 3494766
[TBL] [Abstract][Full Text] [Related]
12. Augmented inhibition of tumor cell proliferation in the combined use of disulfiram with ascorbic acid and the involvement of oxygen free radicals.
Mashiba H; Matsunaga K
Jpn J Exp Med; 1990 Aug; 60(4):209-14. PubMed ID: 2292808
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
Qin Z; Blankenstein T
Cancer Res; 1995 Nov; 55(21):4747-51. PubMed ID: 7585497
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
Palladino MA; Shalaby MR; Kramer SM; Ferraiolo BL; Baughman RA; Deleo AB; Crase D; Marafino B; Aggarwal BB; Figari IS
J Immunol; 1987 Jun; 138(11):4023-32. PubMed ID: 3295044
[TBL] [Abstract][Full Text] [Related]
15. Human alpha lymphotoxin (LT): studies examining the mechanism(s) of LT-induced inflammation and tumor destruction in vivo.
Jeffes EW; Averbook BJ; Ulich TR; Granger GA
Lymphokine Res; 1987; 6(2):141-9. PubMed ID: 3495706
[TBL] [Abstract][Full Text] [Related]
16. Therapy combining tumor necrosis factor with tumor-specific antibody against Meth A sarcoma.
Satomi N; Sakurai A; Haranaka R; Haranaka K
J Biol Response Mod; 1989 Oct; 8(5):528-38. PubMed ID: 2677250
[TBL] [Abstract][Full Text] [Related]
17. Tumoricidal activity of lymphotoxin (tumor necrosis factor beta) in vivo: its effects on macrophages.
Higuchi M; Mitsuno T; Sugimoto M; Okamoto A; Hirose S; Tsukita S; Osawa T
J Biol Response Mod; 1988 Dec; 7(6):619-30. PubMed ID: 3265149
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.
Mackay F; Bourdon PR; Griffiths DA; Lawton P; Zafari M; Sizing ID; Miatkowski K; Ngam-ek A; Benjamin CD; Hession C; Ambrose CM; Meier W; Browning JL
J Immunol; 1997 Oct; 159(7):3299-310. PubMed ID: 9317128
[TBL] [Abstract][Full Text] [Related]
19. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
20. Augmented inhibition of MethA tumor cell proliferation in combined use of diethyldithiocarbamate with catalase or by a nondialysable fraction from co-incubation.
Mashiba H; Matsunaga K
Toxicol Lett; 1993 Jan; 66(1):97-104. PubMed ID: 8381244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
